Day: September 30, 2021

Includes support for the recommendations of the Task Force on Climate-related Financial DisclosuresROHM 2030 Greenhouse Gas Emission ReductionROHM has revised their greenhouse gas emission reduction target for 2030 from 30% (set in 2018) to 50.5%Santa Clara, CA and Kyoto, Japan, Sept. 30, 2021 (GLOBE NEWSWIRE) — ROHM Semiconductor today announced it has revised its medium-term environmental targets for 2030 with the aim of achieving a carbon-free society. Concurrently, ROHM has agreed to endorse the recommendations of the Task Force on Climate-related Financial Disclosures (TCFD) and work on information disclosure in line with these recommendations. Recognizing that climate change is one of the most important issues affecting the company’s business activities, ROHM has set a goal of achieving zero carbon (virtually...

HOUSTON, Sept. 30, 2021 (GLOBE NEWSWIRE) — Kirby Corporation (“Kirby”) (NYSE: KEX) will announce its 2021 third quarter results at 6:00 a.m. Central Daylight Time (“CDT”) on Thursday, October 28, 2021. This announcement will be followed by an earnings conference call webcast at 7:30 a.m. CDT. To listen to the webcast, please visit the Investor Relations section of Kirby’s website at www.kirbycorp.com. For listeners who wish to participate in the question and answer session of the webcast, you may access the call by dialing 866-691-5839 within the U.S. and Canada or +1 409-216-0840 internationally. The conference ID for the call is 9778118. A replay of the webcast will be available for a period of one year by visiting the Investor Relations section of Kirby’s website. The financial and other information to be discussed...

TORONTO, Sept. 30, 2021 (GLOBE NEWSWIRE) — Kinross Gold Corporation (TSX:K; NYSE:KGC) will release its financial statements and operating results for the third quarter of 2021 on Wednesday, November 10, 2021, after market close. On Thursday, November 11, 2021 at 8:00 a.m. ET Kinross will hold a conference call and audio webcast to discuss the results, followed by a question-and-answer session. The call-in numbers are as follows: Canada & US toll-free – (833) 968-2237; Passcode: 6608479Outside of Canada & US – (825) 312-2059; Passcode: 6608479 Replay (available up to 14 days after the call): Canada & US toll-free – (800) 585-8367; Passcode: 6608479Outside of Canada & US – +1 (416) 621-4642; Passcode: 6608479 You may also access the conference call on a listen-only basis via webcast at our website www.kinross.com....

Preliminary clinical data from Phase 1/2 study still anticipated in Q4 SAN MATEO, Calif. and CAMBRIDGE, Mass., Sept. 30, 2021 (GLOBE NEWSWIRE) — Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced that it will present preclinical data in a poster at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics. The meeting will be held from Oct. 7-10, 2021. The poster will include preclinical data on the pharmacokinetics and pharmacodynamics of KB-0742, Kronos Bio’s internally discovered oral CDK9 inhibitor. The data build on results first shared at the American Association for Cancer Research (AACR) meeting earlier this year. The investigational compound, which is being developed for the treatment of MYC-amplified solid tumors,...

CAMBRIDGE, Mass. and NEW YORK, Sept. 30, 2021 (GLOBE NEWSWIRE) — Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of MasterKey therapies, today announced the presentation of pre-clinical data for three pipeline programs in oral and poster sessions at the upcoming AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics being held October 7-10, 2021. Oral presentation information is as follows: Title: BDTX-1535, a CNS penetrant MasterKey inhibitor of common, uncommon and resistant EGFR mutations, demonstrates in vivo efficacy and has potential to treat osimertinib-resistant NSCLC with or without brain metastasesSession Title: Plenary Session 2: New Drugs on the Horizon IAbstract Number: 5208Presentation Date: Friday,...

HOUSTON, Sept. 30, 2021 (GLOBE NEWSWIRE) — Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid tumors, and other cancers, and Nationwide Children’s Hospital disclosed today that an abstract has been accepted by the American Association for Cancer Research (AACR) for poster presentation at the 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics. The abstract highlights research into the ability of Salarius’ lead drug candidate, seclidemstat (SP-2577), to target FET-rearranged sarcomas through the inhibition of the non-enzymatic function (i.e., scaffolding function) of the LSD1 enzyme. The conference will take place virtually October 7–10, 2021. The title and authors of...

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Sept. 30, 2021 (GLOBE NEWSWIRE) — Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the publication of the abstract titles and authors for two posters that will be presented at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics being held October 7-10, 2021. Presentation Details: Zenocutuzumab Title: Zenocutuzumab is an effective HER2/HER3 Biclonics® antibody in cancers with NRG1 fusionsAuthors: Jan Gerlach, Igor Odintsov, Alexandre Deshiere, Ron Schackmann, Marc Ladanyi, Jeroen Lammerts van Bueren, Romel Somwar, Cecile GeuijenVirtual Poster #: P201 MCLA-158 (petosemtamab) Title:...

Company to host conference call and webcast Thursday, October 7, 2021, at 9:00 a.m. ET SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Sept. 30, 2021 (GLOBE NEWSWIRE) — ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced three poster presentations at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics to be held October 7-10, 2021. Details of the poster presentations are as follows:  Title: Initial results from a Phase 1b study of ORIC-101, a glucocorticoid receptor antagonist, in combination with enzalutamide in patients with metastatic prostate cancer  Poster #: P041       Title: Biomarker results supporting selection of RP2D from a Phase 1b study of ORIC-101,...

BOSTON, Sept. 30, 2021 (GLOBE NEWSWIRE) — Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue precision medicines, today announced that preclinical data for the company’s GSPT1-directed molecular glue degrader targeting Myc-driven breast cancer has been selected for a late-breaking poster presentation at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics from Oct. 7-10. Presentation Details:Title: Identification of GSPT1-mediated molecular glue degraders for the treatment of Myc-driven cancersPresenter: Gerald Gavory, Ph.D.Poster Number: LBA004Date/Time: Available on-demand throughout conference About Monte RosaMonte Rosa Therapeutics is a biotechnology company developing a portfolio of novel molecular glue degrader precision medicines....